Remove Class Remove Funding Remove Pricing Remove San Diego
article thumbnail

TuSimple Prices IPO, Starts Trading Today

socalTECH

San Diego-based TuSimple priced its IPO last night, saying that it will sell 33,783,783 shares of its Class A common stock at the price of $40.00 Composite Capital Master Fund, and Navistar. per share, raising just over $1 billion for the company. Piper Sandler and Valuable Capital.

Pricing 113
article thumbnail

VelosBio Finds $137M For Oncology Efforts

socalTECH

San Diego-based biopharmaceuticals developer VelosBio says it has raised $137M in a Series B funding roudn, to go towards its oncology efforts. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company, as well as the company's existing investors.

San Diego 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Xconomy

Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years. The amount raised surpassed expectations.

article thumbnail

How Doctors Think About Drug Prices

Xconomy

There are a lot of factors involved in drug pricing that don’t enter my head when I’m seeing a patient. Simplistic as this framework is, it goes a long way to describing how we should think about drug pricing. Suffice it to say that drug companies should set a price that is within reason. Nor has the word “rebate.”

Pricing 40
article thumbnail

Interview with Bong Koh, LifeCrowd

socalTECH

The firm is initially focusing on the Los Angeles market, and connecting people with fun, interesting classes, activities, and more in the local area. We want to create the right mix of the types of activities, price points, and make sure we have high quality content and high quality activities.

Startup 271
article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.

article thumbnail

Interview with Noah Auerhahn, Extrabux

socalTECH

For this morning's interview, we talked with Noah Auerhahn , President of San Diego-based Extrabux (www.extrabux.com), an online site focused on providing consumers with comparison shopping combined with discount offers. Finally, what are you using your recent funding round for? Noah, thanks for the interview.

USC 207